Real‐world evidence of secukinumab in psoriasis treatment–a meta‐analysis of 43 studies.

Augustin M , Jullien D , Martin A , Peralta C

Abstract

Meta-analyses of real-world evidence (RWE) studies provide valuable insights from unselected patient populations in routine clinical practice. Secukinumab, the first fully human monoclonal antibody that selectively neutralizes IL-17A, has shown long lasting effectiveness and safety in moderate to severe plaque psoriasis (PsO). Since its license approval in 2015, many RWE studies have been published. Here, we reviewed all available literature on RWE studies involving secukinumab in patients with moderate to severe PsO to evaluate its effectiveness, drug survival and safety. Materials and methods https://www.embase.com and https://clinicaltrials.gov databases were searched using pre-specified inclusion criteria from 1/1/2015 to 31/5/2019. Outcomes were measured at 3, 6, and 12 months, and analyzed using a meta-package and R statistical software.

More Publications

Omalizumab for IgE-mediated food allergy: A systematic review and meta-analysis

Zuberbier T , Wood RA , Bindslev-Jensen C , Fiocchi A , Chinthrajah S , Worm M , Deschildre A , Rivas MF , Santos A , Jaumont JX , Tassinari P

Dec, 2022

The Journal of Allergy and Clinical Immunology: In Practice

Efficacy and safety of bisoprolol compared to other selective beta-1 blockers in the treatment of hypertension: a systematic review and meta-analysis of randomized parallel clinical trials

U Jadhav , T Nair , S Bansal , S Ray

Oct, 2021

European Heart Journal

Effect of omalizumab on glucocorticoid use and lung function in the treatment of allergic bronchopulmonary aspergillosis in people with cystic fibrosis: a systematic review and meta-analysis

Meiling Jin , Jo A. Douglass , J. Stuart Elborn , Slawomir Lazarewicz , Xavier Jaumont , Meng Yan , Ritesh Agarwal, , William J. Calhoun,

Dec, 2022

The Journal of Allergy and Clinical Immunology